This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma

This study has been completed.
Information provided by (Responsible Party):
Gilead Sciences Identifier:
First received: February 25, 2011
Last updated: October 27, 2016
Last verified: October 2016

The primary objectives of this study is to evaluate the safety and efficacy of idelalisib (GS-1101, CAL-101) in participants with previously treated indolent non-Hodgkin lymphoma (iNHL).

Eligible patients will initiate oral therapy with idelalisib at a starting dose of 150 mg twice per day. Treatment with idelalisib can continue in compliant participants for up to twelve 28-day cycles of idelalisib. Participants who appear to be benefiting from treatment at the completion of 12 cycles of treatment with idelalisib may be eligible for participation in a long-term safety extension study of idelalisib.

Condition Intervention Phase
Indolent Non-Hodgkin's Lymphoma Follicular Lymphoma Small Lymphocytic Lymphoma Marginal Zone Lymphoma Drug: Idelalisib Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Single-agent Idelalisib for Previously Treated Low-grade Lymphoma: A Phase 1/2 Study of Safety, Efficacy, and Flow-cytometric Assessment of Tumor-cell Signaling Events

Resource links provided by NLM:

Further study details as provided by Gilead Sciences:

Primary Outcome Measures:
  • Overall Safety of Idelalisib [ Time Frame: 30 days post last study treatment (up to 12 months) ]
    The overall safety of idelalisib was assessed as the percentage of participants experiencing treatment-emergent adverse events (AEs; Serious AEs, Grade ≥ 3 AEs, AEs related to idelalisib, and AEs leading to discontinuation of idelalisib).

  • Clinical Response: Overall Response Rate [ Time Frame: Up to twelve 28-day cycles (maximum of 12 months) ]

    Participants were assessed for clinical response by appropriate imaging at the end of cycles 3, 6, 9, and 12.

    Overall response rate (ORR) was assessed based on standardized criteria (Cheson 2007), and was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) based on investigator assessment after the start of idelalisib treatment until progression or the end of study drug treatment.

    • CR was defined as the disappearance of all evidence of disease.
    • PR was defined the regression of measurable disease and no new sites.

Secondary Outcome Measures:
  • Flow Cytometric Measurement of Constitutive or Inducible Phosphorylation of Akt (at S473) and S6 Within Tumor B Cells [ Time Frame: Up to twelve 28-day cycles (maximum of 12 months) ]
  • Flow Cytometric Measurement of Tumoral and Peripheral Blood T and NK Cells [ Time Frame: Up to twelve 28-day cycles (maximum of 12 months) ]
  • Changes in Concentration of Peripheral Blood Chemokines and Cytokines [ Time Frame: Up to twelve 28-day cycles (maximum of 12 months) ]
  • Changes in Liver Imaging as Assessed by Magnetic Resonance Imaging (MRI) and Gadoxetic Acid (GD-EOB-DTPA) Contrast [ Time Frame: Up to twelve 28-day cycles (maximum of 12 months) ]

Enrollment: 18
Study Start Date: February 2011
Study Completion Date: August 2015
Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Idelalisib Drug: Idelalisib
Tablet(s) administered orally twice daily
Other Names:
  • GS-1101
  • CAL-101
  • Zydelig®


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Previously treated relapsed or refractory B-cell iNHL
  • Provide written informed consent

Exclusion Criteria:

  • Pregnant or nursing
  • Active, serious infection requiring systemic therapy
  • Positive test for HIV antibodies
  • Active hepatitis B or C viral infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01306643

United States, California
Stanford Cancer Center
Palo Alto, California, United States, 94304-5548
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029
Sponsors and Collaborators
Gilead Sciences
Study Director: Gilead Study Director Gilead Sciences
  More Information

Responsible Party: Gilead Sciences Identifier: NCT01306643     History of Changes
Other Study ID Numbers: 101-10
Study First Received: February 25, 2011
Results First Received: August 23, 2016
Last Updated: October 27, 2016

Keywords provided by Gilead Sciences:
Indolent Non-Hodgkin's Lymphoma
Non-Hodgkin Lymphoma
Phosphatidylinositol 3-kinase
Follicular Lymphoma (FL)
Small Lymphocytic Lymphoma (SLL)
Marginal Zone Lymphoma (MZL)

Additional relevant MeSH terms:
Lymphoma, Follicular
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell, Marginal Zone
Lymphoma, B-Cell
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Leukemia, Lymphoid
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017